top of page

Free Biopharma Daily Stock Updates - 07/27/21

  • Writer: BPIQ
    BPIQ
  • Jul 27, 2021
  • 2 min read

$XBI $122.98 -1.0%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Pipeline Updates

$ARNA -3.9% Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases. source


$SLGL -0.9% Sol-Gel Technologies Announces FDA Approval of TWYNEO®. source


$MDNA +5.5% Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference. source


$IBRX -0.7%ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent. source


$KRON -1.2% Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML). source


$LTRN -1.9% Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S. source


$RLMD +2.0% Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential. source


$INFI -31.5% Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC). source


$BBIO -4.6% BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations. source


$TNXP +4.3% Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs. source


$AZN +1.2% AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity. source


$VSTM -1.5% Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021. source


$PSTV -10.6% Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement. source


$BCLI +0.9% BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel. source


$OBSV +13.9% Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor. source


$ITRM +17.5% On 7/26 Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem. source



Financial Updates

$IMAB -3.5% I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange. source

Posted by FS

 
 
 

Comments

bottom of page